Anzeige
Mehr »
Donnerstag, 30.10.2025 - Börsentäglich über 12.000 News
Die 80-Milliarden-Dollar-Nuklear-Renaissance: Warum Uran der heißeste Sektor der Welt ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AR5F | ISIN: CH0329023102 | Ticker-Symbol: IMR
Tradegate
29.10.25 | 20:58
3,370 Euro
+2,28 % +0,075
1-Jahres-Chart
AC IMMUNE SA Chart 1 Jahr
5-Tage-Chart
AC IMMUNE SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,2203,34029.10.
3,2303,35529.10.

Aktuelle News zur AC IMMUNE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrAC Immune reports first TDP-43 PET tracer characterization in study62
FrAC Immune SA: First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine26
25.09.AC Immune SA: Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine389Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed Phase 1b/2a trial of ACI-35.030 and JACI-35.054...
► Artikel lesen
25.09.AC Immune's Alzheimer's immunotherapy shows promising results89
04.09.AC Immune cuts workforce by 30%, trims pipeline to preserve cash47
04.09.AC Immune SA - 6-K, Report of foreign issuer8
AC IMMUNE Aktie jetzt für 0€ handeln
04.09.AC Immune SA: AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway486AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce...
► Artikel lesen
05.08.AC Immune: EPS verfehlt Schätzungen um 0,04 CHF - Umsatz schlechter als erwartet117
05.08.AC Immune SA: AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update429AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical...
► Artikel lesen
05.08.AC Immune SA - 6-K, Report of foreign issuer8
20.06.AC Immune SA - 6-K, Report of foreign issuer73
11.06.AC Immune SA - 6-K, Report of foreign issuer30
19.05.AC Immune SA - 6-K, Report of foreign issuer64
30.04.AC Immune SA: AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update1.590AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive...
► Artikel lesen
13.03.AC Immune SA: AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update549AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential...
► Artikel lesen
10.12.24AC Immune SA: AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome512AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,6